Company type | Aktiengesellschaft |
---|---|
WBAG: ICLL OTCQX: INRLY | |
Industry | Biotechnology |
Founded | 1998 |
Defunct | 2013 |
Fate | Merged with Vivalis SA |
Successor | Valneva SE |
Headquarters | , |
Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
Products | Development of vaccines |
Revenue | €34.2 million (2010)[1] |
(€251.2 million) (2010)[1] | |
(€255.2 million) (2010)[1] | |
Total assets | €225.2 million (end 2010)[1] |
Total equity | €121.1 million (end 2010)[1] |
Number of employees | 410 (average, 2010)[1] |
Website | www |
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.